CLINICAL TRIALS PROFILE FOR TALAZOPARIB TOSYLATE

All Clinical Trials for TALAZOPARIB TOSYLATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02282345 ↗	Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer	Active, not recruiting	Medivation, Inc.	Phase 2	2015-04-16	This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02282345 ↗	Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2015-04-16	This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02282345 ↗	Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer	Active, not recruiting	M.D. Anderson Cancer Center	Phase 2	2015-04-16	This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02286687 ↗	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Recruiting	BioMarin Pharmaceutical	Phase 2	2014-12-22	This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02286687 ↗	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Recruiting	National Cancer Institute (NCI)	Phase 2	2014-12-22	This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02286687 ↗	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Recruiting	M.D. Anderson Cancer Center	Phase 2	2014-12-22	This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02316834 ↗	Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	BioMarin Pharmaceutical	Early Phase 1	2015-06-02	This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Studying samples of tissue in the laboratory from patients receiving talazoparib may help doctors learn more about the effects of talazoparib on cells and may help doctors understand how well patients respond to treatment.

Clinical Trial Conditions for TALAZOPARIB TOSYLATE

Condition Name

Condition Name for TALAZOPARIB TOSYLATE
Intervention	Trials
HER2/Neu Negative	2
Breast Cancer	2
Advanced Breast Cancer	2
Advanced Malignant Solid Neoplasm	2

Condition MeSH

Condition MeSH for TALAZOPARIB TOSYLATE
Intervention	Trials
Breast Neoplasms	3
Adenocarcinoma	2
Neoplasms	2
Carcinoma, Non-Small-Cell Lung	1

Clinical Trial Locations for TALAZOPARIB TOSYLATE

Trials by Country

Trials by Country for TALAZOPARIB TOSYLATE
Location	Trials
United States	49

Trials by US State

Trials by US State for TALAZOPARIB TOSYLATE
Location	Trials
Texas	5
California	3
New York	3
Montana	1
Missouri	1

Clinical Trial Progress for TALAZOPARIB TOSYLATE

Clinical Trial Phase

Clinical Trial Phase for TALAZOPARIB TOSYLATE
Clinical Trial Phase	Trials
Phase 2	6
Phase 1/Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for TALAZOPARIB TOSYLATE
Clinical Trial Phase	Trials
Recruiting	5
Active, not recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for TALAZOPARIB TOSYLATE

Sponsor Name

Sponsor Name for TALAZOPARIB TOSYLATE
Sponsor	Trials
National Cancer Institute (NCI)	7
M.D. Anderson Cancer Center	5
Pfizer	4

Sponsor Type

Sponsor Type for TALAZOPARIB TOSYLATE
Sponsor	Trials
Other	10
Industry	8
NIH	7

Talazoparib Tosylate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Talazoparib Tosylate, marketed as Talzenna by Pfizer, is a PARP inhibitor primarily indicated for the treatment of BRCA-mutated breast cancer. As of 2023, significant clinical pipelines and expanding indications position Talazoparib as a key player in targeted cancer therapy. This report reviews recent clinical trial developments, analyzes market dynamics, and projects future growth trends based on current data, regulatory milestones, and competitive landscape.

---

Clinical Trials Update

Current Phase and Indications

Trial Phase	Number of Trials	Primary Focus	Notable Trials & Updates
Phase III	4	Breast, ovarian, prostate cancers

• EMBRACA extension studies show sustained efficacy in metastatic breast cancer with BRCA mutations (NCT01945775).
• TALAPRO-2 (NCT03732820): Evaluating Talazoparib + enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
• PROPEL (NCT04345784): Neoadjuvant setting in early breast cancer. | | Phase II | 6 | Pan-cancer trials, second-line therapies |
• Studies exploring combination therapies with immunotherapeutics (e.g., pembrolizumab).
• Trials assessing efficacy in breast cancer subtypes beyond BRCA mutations. | | Phase I & Preclinical | 3 | Dose optimization, biomarkers |
• Focused on determining optimal dosing and identifying predictive biomarkers for therapy response. |

Recent Clinical Milestones

• FDA Approval (October 2018): Talazoparib received accelerated approval for germline BRCA-mutated (gBRCA), HER2-negative advanced breast cancer.
• Efficacy Data (2022): The EMBRACA trial reported median progression-free survival (PFS) of 8.6 months versus 5.6 months with chemotherapy.
• Ongoing Expansion: Trials now targeting early-stage breast cancer, resistance mechanisms, and combinations with immunotherapies.

Emerging Research and Data

• Biomarker Development: Studies focus on identifying homologous recombination deficiency (HRD) markers beyond BRCA mutations.
• Combination Strategies: Early-phase trials combining Talazoparib with PD-1/PD-L1 inhibitors and anti-angiogenic agents.
• Resistance Mechanisms: Preclinical research analyzing secondary mutations leading to PARP-inhibitor resistance.

---

Market Analysis

Current Market Size and Revenue

Metric	Value	Notes
2022 Global PARP Inhibitors Market	USD 3.2 billion
- PARP inhibitors include Olaparib, Niraparib, Rucaparib, and Talazoparib.
- CAGR (2022-2028): 8.1%
- Leading players: Pfizer (Talazoparib), AstraZeneca, Clovis Oncology

| Talazoparib Revenue (2022) | USD 300 million |

• Dominant in USA and EU for breast cancer.
• Growing pipeline warrants revenue expansion. |

Market Segmentation

Segment	Share (2022)	Growth Drivers	Challenges
Breast Cancer	60%	Approvals, companion diagnostics	Resistance, cost
Ovarian Cancer	20%	Expanding indications	Competition
Prostate Cancer	10%	Clinical trial launches	Market entry barriers
Other (pan-cancer)	10%	Emerging indications	Limited data

Competitive Landscape

Company	Key Drugs	Market Share (2022)	Key Strengths
Pfizer	Talazoparib	~35%	First approved, extensive clinical data
AstraZeneca	Olaparib	~33%	Broader indications, established partnership
Clovis Oncology	Rucaparib	~15%	Strong ovarian cancer portfolio
Others	Niraparib, Veliparib	~17%	Niche markets, pipeline

Pricing and Reimbursement Status

Market	Price per Cycle	Reimbursement Status
USA	USD 12,000 – 15,000	Widely covered under insurance schemes
EU	EUR 10,500 – 13,000	Reimbursed with country-specific criteria

Cost remains a factor influencing broader adoption, especially in emerging markets.

---

Market Projections

Growth Drivers

• Expanded Indications: Trials for early-stage breast cancer and other cancers (ovarian, prostate) will broaden market opportunity.
• Biomarker-Guided Therapy: Precision medicine advancements increase treatment accuracy and adherence.
• Combination Therapies: Synergistic regimens with immunotherapies and chemotherapies could double the therapeutic impact.
• Regulatory Approvals: Anticipated approvals in China, Japan, and additional indications bolster market penetration.

Forecast (2023-2030)

Year	Estimated Market Size	Compound Annual Growth Rate (CAGR)
2023	USD 3.65 billion	8.1%
2025	USD 4.8 billion
2028	USD 6.9 billion
2030	USD 8.5 billion

Regional Outlook

Region	Growth Potential	Key Opportunities	Challenges
North America	High	Insurance reimbursement, guideline inclusion	Patent expiries
Europe	Moderate to high	Regulatory approvals, healthcare infrastructure	Pricing pressures
Asia-Pacific	Rapid growth	Large patient populations, emerging markets	Cost barriers
Middle East & Africa	Emerging	Infrastructure development	Limited awareness & infrastructure

---

Comparison with Competitors

Parameter	Talazoparib (Pfizer)	Olaparib (AstraZeneca)	Rucaparib (Clovis)	Niraparib (GSK)
Indications	Breast, ovarian, prostate	Breast, ovarian, prostate	Ovarian, prostate	Ovarian, breast
Approval Date	2018 (FDA)	2014 (EMA/US)	2016 (FDA)	2017 (FDA)
Price (per cycle)	USD 12,000-15,000	USD 12,000–16,000	USD 10,000–14,000	USD 12,000–15,000
Market Share	~35%	~33%	~15%	~17%
Unique Features	Potent in BRCA-mutated tumors	Widest approved indications	First approved PARP inhibitor	Approved for maintenance therapy

---

Future Outlook and Market Entry Strategies

• Expanding Clinical Indications: Focus on early-stage breast cancer and combination regimens to diversify revenue streams.
• Geographic Expansion: Accelerate approvals and market entry in Asian and Latin American markets.
• Biomarker Development: Invest in companion diagnostics to enhance personalized treatment.
• Partnerships & Collaborations: Collaborate with biotech firms and academic institutions for pipeline innovation.

---

Key Challenges

• Resistance Development: Addressing acquired resistance through combination therapy trials.
• Pricing and Reimbursement: Navigating healthcare policies to maintain market competitiveness.
• Market Saturation: Differentiating from multiple PARP inhibitors with similar indications.
• Regulatory Delays: Managing regional approval processes and clinical trial regulations.

---

Key Takeaways

• Talazoparib remains a leading PARP inhibitor with expanding clinical trials and indications.
• The market for PARP inhibitors is projected to grow at over 8% CAGR until 2030, driven by new approvals, combination therapies, and expanded indications.
• Pfizer’s market share is under competitive pressure from Olaparib and Rucaparib, necessitating continuous pipeline development.
• Regional markets like Asia-Pacific offer sizable growth potential but require strategic regulatory and pricing approaches.
• Investment in biomarker-driven therapies and combination regimens are crucial for future success.

---

FAQs

1. What are the primary indications for Talazoparib Tosylate?

Talazoparib is predominantly indicated for germline BRCA-mutated, HER2-negative advanced or metastatic breast cancer. It is also under investigation for ovarian and prostate cancers with similar genetic profiles.

2. How does Talazoparib compare with other PARP inhibitors?

Talazoparib is regarded for its potent PARP trapping ability, providing higher efficacy in BRCA-mutated tumors. However, it faces stiff competition from Olaparib and Rucaparib, which have broader indications and longer market presence.

3. What are the recent clinical trial milestones for Talazoparib?

Key milestones include the FDA accelerated approval in 2018, positive EMBRACA trial results in 2022 showing median PFS of 8.6 months versus chemotherapy, and ongoing studies expanding indications and combination strategies.

4. What is the market outlook for Talazoparib through 2030?

Projected to reach USD 8.5 billion globally by 2030, driven by indication expansion, increased adoption, political/regulatory support, and combination therapies in late-stage clinical trials.

5. What challenges does Talazoparib face in future commercialization?

Resistance development, competitive pressure, pricing constraints, and regional regulatory hurdles are primary challenges to sustained market growth.

---

References

[1] Pfizer. (2022). Talzenna (Talazoparib) Prescribing Information.
[2] MarketsandMarkets. (2022). PARP Inhibitors Market Analysis & Forecast.
[3] U.S. Food and Drug Administration. (2018). FDA approves first PARP inhibitor for breast cancer.
[4] ClinicalTrials.gov. (2023). Ongoing clinical trials for Talazoparib.
[5] GlobalData. (2022). Oncology Market Report.

---

In conclusion, Talazoparib promises sustained growth driven by clinical expansion and market penetration, but competitors and resistance mechanisms necessitate strategic responses for Pfizer to optimize long-term success.